CEO Appointment

June 01, 2016

We are pleased to announce the appointment of Jeremy Haigh as a director and CEO of the Company on 1st June 2016 as indicated in the press release to shareholders dated 18th May 2016. He is a strong advocate of Precision Medicine and will bring numerous industry contacts and considerable commercial experience to the role.

Adding Precision to Medicine - Annual Report and Accounts 2015

May 31, 2016
We have benefitted from a good performance in all aspects of the business in 2015, in particular biomarker services where there has been strong customer adoption of SysQuant® and TMTcalibrator™ with the focus on Precision Medicine. Considerable scientific progress has been made over the period, particularly in Alzheimer’s disease (Ad) across a number of different areas and these have formed…

CEO Appointment

May 18, 2016

Against the buoyant background and trajectory of the PS Biomarker Services business it is now appropriate to expand the executive team with a senior figure strongly connected to the pharmaceutical industry and to split the role of Executive Chairman.

Preliminary Results for Year Ended December 31st, 2015

May 18, 2016

The current year started well with a strong order book, increasing amounts of repeat business and a growing pipeline in biomarker services. With the level of SysQuant® /TMTcalibrator™ production doubled the increased capacity is being fully utilised at a time when the volume of customer enquiries is rising on a monthly basis and we are looking to further expand the sales team. Current indications point to a strong performance in 2016. 

Block Admission Report

April 05, 2016

Deep Protein Profiling Key To Improving Cancer Treatment

April 05, 2016

As global experts in mapping and analysis of protein changes in systems-wide biology, Proteome Sciences plc is strongly encouraged by two recent reports that emphasize the importance of protein profiling to improve outcomes in cancer treatment.

Trading Update

February 29, 2016

After closing 2015 with a good increase in revenues in the second half, the current year has started well with a strong order book and a growing pipeline in biomarker services.

Director Dealing

January 08, 2016

The Company has received notification from Vulpes Life Sciences Fund (“Vulpes”) that it has a total direct and indirect interest in 36,573,125 ordinary shares of 1p each in the capital of the Company (“Ordinary Shares”) equivalent to 16.04% of Proteome Sciences’ total issued share capital.

CK1d Inhibitors Reduce Alzheimer’s Tau Phosphorylation

November 05, 2015

From the 8th Clinical Trials on Alzheimer’s Disease in Barcelona, PS announces that a recently completed study testing its proprietary inhibitors of CK1d reduced the level of tau phosphorylation in a second in vivo model of Alzheimer’s disease tauopathy.